Skip to Content
  • Previous Rank
    224
  • Revenues ($M)
    $15,281.0
  • Revenue Percent Change
    17.5%
  • Profits ($M)
    $4,046.0
  • Profits Percent Change
    37.6%
  • Assets ($M)
    $35,480.0
  • Employees
    8,852

The biopharmaceutical company is the maker of Thalomid and various other drugs that treat multiple myeloma, inflammatory diseases, and various forms of cancer.

Company Info

CEO
Mark J. Alles
CEO Title
Chairman & Chief Executive Officer
Sector
Health Care
Industry
Pharmaceuticals
HQ Location
Summit, N.J.
Websitehttp://www.celgene.com
Years on Fortune 500 List8
Employees8,852
Created with sketchtool.Created with sketchtool.Looking for leads, investment insights, or competitive intelligence?Purchase Now

Celgene Rank History

placeholder

Key Financials (Last Fiscal Year)

$ millions% change
Revenues ($M)$15,281.017.5%
Profits ($M)$4,046.037.6%
Assets ($M)$35,480.0-
Total Stockholder Equity ($M)$6,161.0-

Profit Ratios

Profit as % of Revenues26.5%
Profits as % of Assets11.4%
Profits as % of Stockholder Equity65.7%

Earnings Per Share (Last Fiscal Year)

Earnings Per Share ($)5.51
EPS % Change (from 2017)51.4%
EPS % Change (5 year annual rate)26.7%
EPS % Change (10 year annual rate)-

Total Return

Total Return to Investors (2018)-38.6%
Total Return to Investors (5 year, annualized)-5.4%
Total Return to Investors (10 year, annualized)8.8%